{
  "meta": {
    "timestamp": "2025-01-06T13:33:42.744149",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Applied Therapeutics ",
      "symbol": "APLT",
      "analysis": {
        "historical": {
          "risk_score": 85,
          "key_risks": [
            "Regulatory challenges, including FDA rejection of govorestat and a warning letter regarding trial conduct",
            "Financial sustainability risks due to reliance on external funding and equity financing",
            "Clinical trial risks, including potential unfavorable results",
            "Leadership changes and strategic uncertainty following CEO resignation"
          ],
          "controversies": [
            "FDA warning letter raising concerns about trial conduct and compliance with good clinical practices",
            "Securities fraud class-action lawsuit alleging misleading statements about clinical trial data and FDA approval likelihood",
            "Withdrawal of Marketing Authorization Application (MAA) for govorestat in Europe"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Ethical concerns regarding trial conduct highlighted by the FDA warning letter",
            "Potential reputational damage and loss of investor trust due to regulatory and legal challenges"
          ],
          "governance_issues": [
            "Leadership changes, including CEO resignation, introducing strategic uncertainty",
            "Regulatory strategy reevaluation delaying planned filings and market entry"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Applied Therapeutics (APLT) ESG Score and Rating 2024 - MarketBeat",
              "snippet": "According to The Upright Project, which measures holistic value creation and impact of companies, Applied Therapeutics has a net impact ratio of 74.2%, indicating an overall positive sustainability impact. Applied Therapeutics seems to create the most significant positive value in the categories of Creating knowledge, Physical diseases, and Taxes.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:13.001998+00:00",
              "published_date": null,
              "source_hash": "a178888c2a25124acdfee4d74b5a46e9"
            },
            {
              "url": "",
              "title": "Why Did Applied Therapeutics Inc (APLT) Soar? Key Factors Explained",
              "snippet": "Applied Therapeutics Inc (APLT) Stock Trading Recap. On Friday, Applied Therapeutics Inc (APLT) stock saw a modest uptick, ending the day at $0.94 which represents a slight increase of $0.04 or 4.44% from the prior close of $0.9. The stock opened at $0.92 and touched a low of $0.89 during the day, reaching a high of $0.96.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:13.002123+00:00",
              "published_date": null,
              "source_hash": "e5e70c6d6d9628e564d54ae163d91df9"
            },
            {
              "url": "",
              "title": "Applied Therapeutics' SWOT analysis: rare disease biopharma stock faces ...",
              "snippet": "Applied Therapeutics Inc . (NASDAQ: APLT), a biopharmaceutical company specializing in novel treatments for rare diseases, stands at a critical juncture as it navigates regulatory challenges and market opportunities.The company's focus on addressing unmet medical needs in the rare disease space has garnered attention from investors and analysts alike, positioning it as a noteworthy player in ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:13.002139+00:00",
              "published_date": null,
              "source_hash": "0bcdd3e2e895f5df9e7ca59d7b895110"
            },
            {
              "url": "",
              "title": "Examining the Storm Applied Therapeutics, Inc. Faces Legal Challenges ...",
              "snippet": "In recent weeks, Applied Therapeutics, Inc. (NASDAQ: APLT) has become the focal point of investor scrutiny following the announcement of a class action lawsuit alleging that the company made materially false or misleading statements regarding its Phase III INSPIRE trial. This lawsuit, filed by Holzer & Holzer, LLC, comes at a time when the company is showcasing financial strength in some areas ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:13.002152+00:00",
              "published_date": null,
              "source_hash": "99979acee61fa6c637ff4a96b84f7a61"
            },
            {
              "url": "",
              "title": "Understanding the Recent Challenges Faced by Applied Therapeutics",
              "snippet": "Allegations suggest that Applied Therapeutics did not adhere strictly to clinical guidelines, resulting in heightened risks for investors. A detailed examination reveals that missteps in data collection could undermine the entire NDA process, creating an environment of uncertainty for stockholders.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:13.002164+00:00",
              "published_date": null,
              "source_hash": "8e4f2c3b62b1ecd7a205900c0051297b"
            },
            {
              "url": "",
              "title": "Securities and Science The Legal Crossroads of Applied Therapeutics, Inc.",
              "snippet": "The realm of pharmaceutical investments often presents a delicate interplay between innovation and accountability. Recent legal developments concerning Applied Therapeutics, Inc. (NASDAQ: APLT) underscore the significant repercussions of corporate governance and transparency on investor trust and company performance. A series of class action lawsuits initiated against the company and its ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:13.002176+00:00",
              "published_date": null,
              "source_hash": "d2ec4db1ee0827ef81bfffa839c8bbd0"
            },
            {
              "url": "",
              "title": "Exploring Legal Considerations for Applied Therapeutics Investors",
              "snippet": "An in-depth look at the investigation of Applied Therapeutics and its implications for investors following recent disclosures affecting their stock. ... The dramatic fall in share price not only underscores the potential financial risks for investors but also raises broader questions about the reliability of communications from publicly traded ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:13.002187+00:00",
              "published_date": null,
              "source_hash": "27eecef466f69925f4b2c193d1572ab9"
            },
            {
              "url": "",
              "title": "Investor Relations - Applied Therapeutics",
              "snippet": "Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia Nov 07, 2024 Applied Therapeutics Reports Third Quarter 2024 Financial Results",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:13.002197+00:00",
              "published_date": null,
              "source_hash": "14bc9ca18e8087a397c588939fed2abb"
            },
            {
              "url": "",
              "title": "Applied Therapeutics's SWOT analysis: rare disease biotech stock faces ...",
              "snippet": "While specific financial metrics were not provided in the recent analyses, it's worth noting that Applied Therapeutics' stock was trading at $5.63 as of July 17, 2024. The company's financial performance is closely tied to its regulatory progress and market expectations, given its pre-revenue status and focus on drug development.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:13.002210+00:00",
              "published_date": null,
              "source_hash": "881a9c35d971812c4e763caae598fa40"
            },
            {
              "url": "",
              "title": "Applied Therapeutics Reports Second Quarter 2024 Financial - GlobeNewswire",
              "snippet": "Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:13.002220+00:00",
              "published_date": null,
              "source_hash": "f773260d3dad9a10d6b28559efc0176e"
            },
            {
              "url": "",
              "title": "Why Did Applied Therapeutics Inc (APLT) Soar? Key Factors Explained",
              "snippet": "Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company's success and shareholder interests. Currently, insiders own just 25.56% of Applied Therapeutics Inc (APLT)'s shares, while financial institutions hold 88.02%.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:15.677069+00:00",
              "published_date": "2025-01-06T15:40:00+00:00",
              "source_hash": "cdc8ebb848b05dfb9635052e3b2a82ac"
            },
            {
              "url": "",
              "title": "Applied Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Encouraged To Contact The Schall Law Firm",
              "snippet": "Applied Therapeutics failed to adhere to appropriate trial protocol and good clinical practices for its drug candidate, govorestat. These failures created a severe risk that the Company's trial data would be rejected by the FDA when submitted with the ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:15.677172+00:00",
              "published_date": "2025-01-02T17:22:00+00:00",
              "source_hash": "b9d514adb5c50cb630e4e7123e4eebd1"
            },
            {
              "url": "",
              "title": "Law Offices of Frank R. Cruz Encourages Applied Therapeutics, Inc. (APLT) Investors To Inquire About Securities Fraud Class Action",
              "snippet": "The Law Offices of Frank R. Cruz Encourages Applied Therapeutics, Inc. (APLT) Investors To Inquire About Securities Fraud Class Action",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:25.960640+00:00",
              "published_date": "2024-12-30T21:09:00+00:00",
              "source_hash": "9e23d41c9191fc2190bb2facf81eae28"
            },
            {
              "url": "",
              "title": "Deadline Approaching: Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith",
              "snippet": "IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN APPLIED THERAPEUTICS, INC. (APLT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:15.677229+00:00",
              "published_date": "2025-01-03T17:08:00+00:00",
              "source_hash": "800955f50b118eab155e644ef0df9051"
            },
            {
              "url": "",
              "title": "Applied Therapeutics Inc APLT",
              "snippet": "We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics financial sustainability risks",
              "retrieved_at": "2025-01-06T20:33:15.677252+00:00",
              "published_date": "2024-12-27T00:00:00+00:00",
              "source_hash": "eae8ec6fb3f919898b97e9783f529ad0"
            },
            {
              "url": "",
              "title": "Applied Tx's pediatric rare disease prosect hits another snag",
              "snippet": "Even after a failed phase 3 pediatric clinical trial, Applied Therapeutics forged ahead with an FDA filing for potential market approval. Now the regulatory agency has extended the review period ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:19.175767+00:00",
              "published_date": null,
              "source_hash": "9fb2f5e05743df31a66ff4e15a400722"
            },
            {
              "url": "",
              "title": "FDA rejects Applied filing for rare disease approval",
              "snippet": "The FDA has rejected Applied Therapeutics' attempt to win approval on the strength of a failed phase 3 trial, triggering a 75% drop in the biotech's share price. Applied said the complete ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:19.175885+00:00",
              "published_date": null,
              "source_hash": "441e18fe6d4a44839888d482d85171e5"
            },
            {
              "url": "",
              "title": "After Month of Bad News, Applied Shuffles Leadership, Lays Out ...",
              "snippet": "Applied Therapeutics CEO Shoshana Shendelman has stepped down after a month of bad news, including an FDA rejection and a warning letter over the biotech's conduct during a clinical trial. In addition, Applied is reevaluating its regulatory applications for lead asset govorestat and pushing back planned filings for the drug.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:19.175903+00:00",
              "published_date": null,
              "source_hash": "aa8b6521fc5e8caebfa062b410c361a6"
            },
            {
              "url": "",
              "title": "Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited ...",
              "snippet": "An Applied Therapeutics drug widely expected to secure FDA approval has been turned down by the agency, a setback for the company's bid to bring to market the first therapy for a rare inherited ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:19.175919+00:00",
              "published_date": null,
              "source_hash": "4e8c1b6a819299404bcf514abd72f572"
            },
            {
              "url": "",
              "title": "US FDA declines to approve Applied Therapeutics' genetic disease drug",
              "snippet": "Applied Therapeutics said on Wednesday that the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic metabolic disease, casting a cloud over the company's hopes for its ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:19.175931+00:00",
              "published_date": null,
              "source_hash": "9c8cb79cdcee24275cf99fe2b2b16581"
            },
            {
              "url": "",
              "title": "FDA scraps adcomm for Applied's rare disease drug",
              "snippet": "Applied had planned to ask for U.S. approval on the strength of biomarker data, only for the FDA to say it would likely need evidence the drug candidate improves clinical outcomes to receive a ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:19.175944+00:00",
              "published_date": null,
              "source_hash": "cd1901c9e0e17b8a8ac647640770c388"
            },
            {
              "url": "",
              "title": "Applied Therapeutics Crashes After FDA Rejection of Rare ... - BioSpace",
              "snippet": "The FDA last week denied approval for Applied Therapeutics' investigational aldose reductase inhibitor govorestat for the treatment of classic galactosemia, sending the New York biotech's stocks plunging more than 80%.. Galactosemia is a rare genetic metabolic disorder that affects around 3,000 patients in the U.S. It is characterized by the inability to degrade the sugar galactose ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:19.175955+00:00",
              "published_date": null,
              "source_hash": "5dd27b8ac0b6262d1ff9badfaabd1e62"
            },
            {
              "url": "",
              "title": "FDA Extends Review Period for Applied Therapeutics ... - BioSpace",
              "snippet": "Pictured: Facade of the FDA's office in Maryland/iStock, Grandbrothers Applied Therapeutics on Thursday announced that the FDA is extending the review period for its investigational aldose reductase inhibitor govorestat for the treatment of classic galactosemia. The biotech now expects a verdict by Nov. 28, 2024. The FDA will need more time to review supplemental analyses and data that ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:19.175968+00:00",
              "published_date": null,
              "source_hash": "0dcd01f766ad70d4ca6327a70d4dc818"
            },
            {
              "url": "",
              "title": "Applied Therapeutics slumps as FDA seeks more data on lead drug",
              "snippet": "Shares in Applied Therapeutics slumped today after it said it would have to delay a US filing for its lead drug programme AT-007, following an FDA request for more data. The New York-based ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:19.175981+00:00",
              "published_date": null,
              "source_hash": "828911e1f9721969fcc2991e9cf85805"
            },
            {
              "url": "",
              "title": "Applied Therapeutics Provides Regulatory Update on Govorestat for the ...",
              "snippet": "Applied Therapeutics - Company completed Late-Cycle review meeting with FDA - FDA no longer intends to hold Advisory Committee meeting - FDA Review of NDA continues to proceed as planned with ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:19.175993+00:00",
              "published_date": null,
              "source_hash": "e73919c5bb3d03a423fe2fba8597ebe3"
            },
            {
              "url": "",
              "title": "Applied Therapeutics slumps as FDA seeks more data on lead drug",
              "snippet": "Shares in Applied Therapeutics slumped today after it said it would have to delay a US filing for ... the most expeditious path forward to regulatory approval and will provide an update on timing ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:21.914526+00:00",
              "published_date": "2025-01-05T00:00:00+00:00",
              "source_hash": "33c8342bac7c82ac95a960c296a40ce0"
            },
            {
              "url": "",
              "title": "Applied Therapeutics Faces Leadership Changes and Regulatory Hurdles",
              "snippet": "Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks The latest announcement is out from Applied Therapeutics ... company is navigating regulatory challenges ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:21.914643+00:00",
              "published_date": "2024-12-20T12:28:00+00:00",
              "source_hash": "93cd78a0faa7dc5dec1c06e17cc484e6"
            },
            {
              "url": "",
              "title": "Applied Therapeutics sees leadership shuffle, delays drug submission",
              "snippet": "NEW YORK - Applied Therapeutics ... also addressed regulatory hurdles, revealing the withdrawal of its Marketing Authorization Application for govorestat in Europe and a delay in its New Drug ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:21.914678+00:00",
              "published_date": "2024-12-20T07:05:00+00:00",
              "source_hash": "041924bd0a5616757fc77cff0f96e09a"
            },
            {
              "url": "",
              "title": "Warning letter adds to Applied Tx run of bad news",
              "snippet": "Applied Therapeutics has been sent a warning letter ... so the FDA moved ahead with a warning letter. In a regulatory filing, Applied said that the issues raised by the regulator mainly related ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:21.914704+00:00",
              "published_date": "2025-01-04T00:00:00+00:00",
              "source_hash": "05b815a05db6366d1e1b5eb49aaf6106"
            },
            {
              "url": "",
              "title": "APLT STOCK NOTICE: Applied Therapeutics, Inc. Investors are Notified to Contact BFA Law Before Expiration of February 18 Class Action Deadline",
              "snippet": "New York, New York-- (Newsfile Corp. - January 4, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company's senior executives for potential violations of the federal securities laws.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Applied Therapeutics  Applied Therapeutics regulatory approval delays",
              "retrieved_at": "2025-01-06T20:33:21.914727+00:00",
              "published_date": "2025-01-04T14:36:00+00:00",
              "source_hash": "289d780ac37a7013325fdc8b583893ae"
            },
            {
              "url": "",
              "title": "Applied Therapeutics' trial conduct scrutinized in FDA warning letter",
              "snippet": "While Applied Therapeutics has vowed to reapply or appeal the FDA's recent rejection of its rare disease candidate govorestat, deeper issues with the New York biotech's clinical trial conduct ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:23.333189+00:00",
              "published_date": null,
              "source_hash": "a29045e3b0ecd721c4f0af0110c7704d"
            },
            {
              "url": "",
              "title": "Inside the FDA Warning Letter Over the Study of a Rejected Rare Disease ...",
              "snippet": "Following the FDA's rejection of Applied Therapeutics' experimental drug for classic galactosemia, the company announced that it also received a warning letter for the drug's pediatric study. ... The rejection and warning letter are the latest setbacks for govorestat, the drug at the center of this controversy. In clinical trials ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:23.333316+00:00",
              "published_date": null,
              "source_hash": "380e81f936d5c697918a4ca969bea1ac"
            },
            {
              "url": "",
              "title": "Lawsuit alleges Applied misled investors before FDA rejection",
              "snippet": "After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with a resubmission or appeal. But a new lawsuit, filed Dec. 17 in a New York federal ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:23.333334+00:00",
              "published_date": null,
              "source_hash": "96ed7312f700fd7c026312eaadd4e04b"
            },
            {
              "url": "",
              "title": "FDA Warns Applied Therapeutics of 'Objectionable Conditions' in ...",
              "snippet": "Just days after failing to secure approval for govorestat in galactosemia, Applied Therapeutics on Monday announced that it had received a warning letter from the FDA over \"issues\" regarding the biotech's conduct of a clinical trial for the drug candidate.. The regulator raised concerns \"related to electronic data capture,\" according to Applied Therapeutics' SEC filing.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:23.333347+00:00",
              "published_date": null,
              "source_hash": "e4b85a9f798c8db755d0378c6400100d"
            },
            {
              "url": "",
              "title": "Robbins LLP Reminds Investors of the Applied Therapeutics, - GlobeNewswire",
              "snippet": "On this news, Applied Therapeutics' common stock fell to $8.57 per share on November 27, 2024, before falling further to $2.03 on November 29, 2024, and $1.75 per share on December 2, 2024, a ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:23.333359+00:00",
              "published_date": null,
              "source_hash": "10459b3dde752038724cbf3cb40f685c"
            },
            {
              "url": "",
              "title": "Penny Stock Applied Therapeutics' FDA Troubles Trigger ... - Benzinga",
              "snippet": "Following the disclosure, Applied Therapeutics' stock price dropped sharply, which worsened after the company disclosed receiving a warning letter from the FDA on December 2 highlighting ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:23.333369+00:00",
              "published_date": null,
              "source_hash": "959314e4057702b307bc63fdf30865a9"
            },
            {
              "url": "",
              "title": "Applied Therapeutics, Inc. Class Action: Investors are Alerted the ...",
              "snippet": "Applied Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel drug candidates against validated molecular targets in rare diseases. The Company's ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:23.333379+00:00",
              "published_date": null,
              "source_hash": "83df79aea330410a4a97ccfb5d8c0786"
            },
            {
              "url": "",
              "title": "Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit ...",
              "snippet": "Following the disclosure, Applied Therapeutics' stock price dropped sharply, which worsened after the company disclosed receiving a warning letter from the FDA on December 2 highlighting ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:23.333388+00:00",
              "published_date": null,
              "source_hash": "0e9b6fb82bfadb958cd739765d15e79e"
            },
            {
              "url": "",
              "title": "Applied Therapeutics CRL a 'major setback,' says William Blair",
              "snippet": "William Blair says Applied Therapeutics (APLT)' complete response letter from the FDA for govorestat for the treatment of galactosemia is \"unexpected and disappointing.\" Given the lack of ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:23.333398+00:00",
              "published_date": null,
              "source_hash": "09425c0792b5192cbec9824493c0b5a6"
            },
            {
              "url": "",
              "title": "Why Is Applied Therapeutics Stock Trading Lower On Friday? - Applied ...",
              "snippet": "Applied Therapeutics is reviewing the FDA feedback. It plans to immediately request a meeting to discuss the requirements for a potential resubmission of the NDA or appeal of the decision and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:23.333407+00:00",
              "published_date": null,
              "source_hash": "96dc1482963867e9c5ce67483f5e01c5"
            },
            {
              "url": "",
              "title": "Warning letter adds to Applied Tx run of bad news",
              "snippet": "Applied Therapeutics has been sent a warning letter from the FDA over a clinical trial of its rare disease therapy govorestat, which was rejected by the agency last week. The letter - addressed ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:25.960537+00:00",
              "published_date": "2025-01-04T00:00:00+00:00",
              "source_hash": "d409c0012da3d1c9d5c42dc9791f8daa"
            },
            {
              "url": "",
              "title": "Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data",
              "snippet": "A federal securities class-action lawsuit accuses Applied Therapeutics of misleading investors about its trials and drug development. The lawsuit covers investors who purchased Applied ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:25.960670+00:00",
              "published_date": "2024-12-20T17:14:00+00:00",
              "source_hash": "ae36acbb5e401fa25bd654a38c4cbfd9"
            },
            {
              "url": "",
              "title": "Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Applied Therapeutics, Inc. (APLT) Shareholders",
              "snippet": "NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:25.960695+00:00",
              "published_date": "2025-01-06T12:01:00+00:00",
              "source_hash": "6bb2ffb0dbecd3d8715ca6d722550d9f"
            },
            {
              "url": "",
              "title": "Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Applied Therapeutics, Inc. (APLT) Investors",
              "snippet": "Glancy Prongay & Murray LLP (\"GPM\"), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behal",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Applied Therapeutics  Applied Therapeutics clinical trial controversies",
              "retrieved_at": "2025-01-06T20:33:25.960717+00:00",
              "published_date": "2025-01-02T23:49:00+00:00",
              "source_hash": "5c8c914206e286c4413f50b2586abfbb"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Applied Therapeutics financial sustainability risks",
              "rationale": "Investigate the company's reliance on external funding and potential financial instability due to clinical trial uncertainties.",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Applied Therapeutics regulatory approval delays",
              "rationale": "Explore potential risks and historical instances of delays or failures in obtaining FDA or EMA approvals for its drug candidates.",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Applied Therapeutics clinical trial controversies",
              "rationale": "Examine any ethical concerns or controversies related to the conduct or outcomes of the company's clinical trials.",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T13:33:42.744156",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}